Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 7, Number 2—April 2001
4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections

State of the Art

Economic Impact of Antimicrobial Resistance

John E. McGowanComments to Author 
Author affiliation: Emory University School of Medicine, Atlanta, Georgia, USA

Main Article

Table 3

Examples of studies of economic impact of resistance published in 1999-2000

Year First author (ref.) Study methods Features measured
2000 Soriano (9) Case-control, cohort Death, length of hospital stay
2000 Roghmann (10) Cohort Mortality rates at 7 and 30 days, length of hospital stay, direct health-care costs
2000 Vanhems (11) Cohort Death
2000 Simor (12) Comparison of cases with arbitrary criteria Incremental length of hospital stay
2000 Harthug (13) Case-control Death
2000 Bhavnani (14) Case-control Death
2000 Feikin (15) Cohort Death
2000 Garbutt (16) Retrospective cohort Death
1999 Carmeli (17) Cohort Death, length of hospital stay, hospital charges
1999 Rubin (18) Modeling, assumption and extrapolation from case reports Death, direct medical costs
1999 Weingarten (19) Case-control Use of ventilators, length of hospital stay, duration and number of antimicrobial agents, hospital and pharmacy charges
1999 Gonzalez (20) Cohort death
1999 Abramson (21) Case-control Length of hospital stay, attributable median total cost

Main Article

Correction: On July 2, 2001 the following correction was made to this article in the second sentence of paragraph 1. The word "billion" replaced "million" in the phrase "...U.S.$4 to $5 million."